Header

UZH-Logo

Maintenance Infos

Comparison of P2Y12 receptor inhibitors in patients with ST-elevation myocardial infarction in clinical practice: a propensity score analysis of 5 contemporary European registries


De Luca, Leonardo; Zeymer, Uwe; Claeys, Marc J; Dörler, Jakob; Erne, Paul; Matter, Christian M; Radovanovic, Dragana; Weidinger, Franz; Lüscher, Thomas F; Jukema, J Wouter (2020). Comparison of P2Y12 receptor inhibitors in patients with ST-elevation myocardial infarction in clinical practice: a propensity score analysis of 5 contemporary European registries. European Heart Journal - Cardiovascular Pharmacotherapy:Epub ahead of print.

Abstract

INTRODUCTION

Among acute coronary syndromes (ACS), ST-segment elevation myocardial infarction (STEMI) has the most severe early clinical course. Recent randomized clinical trials have demonstrated that novel antithrombotic therapies improve in-hospital outcomes in STEMI patients. We aimed to describe the effectiveness and safety of P2Y12 receptor inhibitors in clinical practice in patients with STEMI based on data from contemporary European ACS registries.

METHODS AND RESULTS

Five registries from the PIRAEUS initiative (AAPCI/ADPAT, ALKK-PIC, AMIS Plus, Belgium STEMI, EYESHOT) provided data for the assessment of P2Y12 receptor inhibitor-based dual antiplatelet therapy. Registries were heterogeneous in terms of setting, patient characteristics and treatment selection. Matched pair analysis and propensity score matching were used to assess all-cause in-hospital death rates based on data from 25'250 patients (8'577 patients on prasugrel, 5'995 on ticagrelor, and 10'678 on clopidogrel). The odds ratio for death of any cause when compared to clopidogrel were 0.72 (CI 0.62 - 0.84, p < 0.001) in favor of the new P2Y12 receptor inhibitors (prasugrel and ticagrelor combined). In the comparison between prasugrel and ticagrelor, there were no relevant differences (OR 0.97; CI 0.77 -1.23, p = 0.81). Event rates of cardiovascular death and stroke were also substantially lower for the new P2Y12 receptor inhibitors. The differences between clopidogrel and prasugrel or ticagrelor on major bleeding were numerically in the same order as for death of any cause, but were not statistically significant. No differences in ischemic and bleeding outcomes were observed between prasugrel and ticagrelor.

CONCLUSION

This analysis suggests that the prasugrel or ticagrelor compared to clopidogrel have favorable outcomes in clinical practice while not being inferior in terms of safety.

Abstract

INTRODUCTION

Among acute coronary syndromes (ACS), ST-segment elevation myocardial infarction (STEMI) has the most severe early clinical course. Recent randomized clinical trials have demonstrated that novel antithrombotic therapies improve in-hospital outcomes in STEMI patients. We aimed to describe the effectiveness and safety of P2Y12 receptor inhibitors in clinical practice in patients with STEMI based on data from contemporary European ACS registries.

METHODS AND RESULTS

Five registries from the PIRAEUS initiative (AAPCI/ADPAT, ALKK-PIC, AMIS Plus, Belgium STEMI, EYESHOT) provided data for the assessment of P2Y12 receptor inhibitor-based dual antiplatelet therapy. Registries were heterogeneous in terms of setting, patient characteristics and treatment selection. Matched pair analysis and propensity score matching were used to assess all-cause in-hospital death rates based on data from 25'250 patients (8'577 patients on prasugrel, 5'995 on ticagrelor, and 10'678 on clopidogrel). The odds ratio for death of any cause when compared to clopidogrel were 0.72 (CI 0.62 - 0.84, p < 0.001) in favor of the new P2Y12 receptor inhibitors (prasugrel and ticagrelor combined). In the comparison between prasugrel and ticagrelor, there were no relevant differences (OR 0.97; CI 0.77 -1.23, p = 0.81). Event rates of cardiovascular death and stroke were also substantially lower for the new P2Y12 receptor inhibitors. The differences between clopidogrel and prasugrel or ticagrelor on major bleeding were numerically in the same order as for death of any cause, but were not statistically significant. No differences in ischemic and bleeding outcomes were observed between prasugrel and ticagrelor.

CONCLUSION

This analysis suggests that the prasugrel or ticagrelor compared to clopidogrel have favorable outcomes in clinical practice while not being inferior in terms of safety.

Statistics

Citations

Dimensions.ai Metrics

Altmetrics

Downloads

4 downloads since deposited on 27 Jan 2021
4 downloads since 12 months
Detailed statistics

Additional indexing

Contributors:PIRAEUS Group
Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > Epidemiology, Biostatistics and Prevention Institute (EBPI)
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:22 January 2020
Deposited On:27 Jan 2021 12:37
Last Modified:27 Jan 2021 12:39
Publisher:Oxford University Press
ISSN:2055-6837
OA Status:Hybrid
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1093/ehjcvp/pvaa002
PubMed ID:31965164

Download

Hybrid Open Access

Download PDF  'Comparison of P2Y12 receptor inhibitors in patients with ST-elevation myocardial infarction in clinical practice: a propensity score analysis of 5 contemporary European registries'.
Preview
Content: Published Version
Filetype: PDF
Size: 406kB
View at publisher
Licence: Creative Commons: Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)